

To: [redacted]@rivm.nl; [redacted]@rivm.nl; [redacted]@umcg.nl; [redacted]@umcg.nl; [redacted]@lumc.nl; [redacted]@lumc.nl

From: [redacted]@rivm.nl

Sent: Mon 11/16/2020 3:42:12 PM

Subject: Moderna Milestones: Phase III data interim analysis & shelf-life stability

Received: Mon 11/16/2020 3:42:28 PM

Moderna Announces Longer Shelf Life for its COVID-19 Vaccine Candidate at Refrigerated Temperatures.pdf
Moderna's COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study.pdf

Dear all,

I hope this finds you well.

On behalf of the whole Moderna team, I wanted to share a quick note to thank you for your time in speaking with us on November 5. We found our discussion interesting and valuable, and wanted to reaffirm that we are available to address any additional questions you may have over the coming weeks and months.

We also wanted to take this opportunity to share two key milestones with you: 1) the first interim analysis of our Phase III study, known as the COVE study, for our COVID-19 vaccine candidate mRNA-1273, and 2) an announcement on longer shelf-life. Both press releases are attached.

Please do not hesitate to reach out should you have any questions.

Best Wishes,

[redacted]

[redacted]

[redacted] Moderna

mobile [redacted] | modernatx.com



Please consider the environment before printing this email

Confidentiality notice and disclaimer: The information in this message and any attachments is intended for the exclusive use of the addressee(s), is confidential and may be privileged or otherwise protected from disclosure. Any review, retransmission, dissemination or other use of, or taking of any action in reliance upon, of any such information by persons or entities other than the intended addressee(s) is prohibited. If you have received this message in error and are not the intended addressee, please notify the sender immediately and delete this message and any attachments from your system without reading or disclosing them. If you are not the intended addressee, be advised that any use of the information in this message and any attachment is prohibited and may be unlawful, and you must not copy this message or attachment or disclose the contents to any other person.